Chemoprevention of prostate cancer with selenium: An update on current clinical trials and preclinical findings

Emmanuelle Meuillet, Suzanne Stratton, Durga Prasad Cherukuri, Anne Christine Goulet, Jacob Kagey, Bruce Porterfield, Mark A. Nelson

Research output: Contribution to journalReview articlepeer-review

74 Scopus citations

Abstract

Prostate cancer is the most common cancer diagnosed and the second leading cause of cancer-related deaths in men in the United States. The etiological factors that give rise to prostate cancer are not known. Therefore, it is not possible to develop primary intervention strategies to remove the causative agents from the environment. However, secondary intervention strategies with selenium (Se) compounds and other agents represent a viable option to reduce the morbidity and mortality of prostate cancer. In this review, we discuss ongoing clinical trials. In addition, we discuss preclinical mechanistic studies that provide insights into the biochemical and molecular basis for the anti-carcinogenic activity of both inorganic and organic forms of Se.

Original languageEnglish (US)
Pages (from-to)443-458
Number of pages16
JournalJournal of Cellular Biochemistry
Volume91
Issue number3
DOIs
StatePublished - 2004

Keywords

  • Anti-carcinogenic activity
  • Morbidity
  • Prostate cancer
  • Selenium
  • Selenomethionine
  • Signaling

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Chemoprevention of prostate cancer with selenium: An update on current clinical trials and preclinical findings'. Together they form a unique fingerprint.

Cite this